DrugPatentWatch Database Preview
Patent: 8,778,923
» See Plans and Pricing
Summary for Patent: 8,778,923
| Title: | GLP-1 receptor modulators |
| Abstract: | The invention relates to compounds that modulate the glucagon-like peptide 1 (GLP-1) receptor, methods of their synthesis, and methods of their therapeutic and/or prophylactic use. Such compounds are act as modulators or potentiators of GLP-1 receptor on their own, or with receptor ligands including GLP-1 peptides GLP-1(7-36) and GLP-1(9-36), or with peptide-based therapies, such as exenatide and liraglutide, and have the following general structure (where \"\" represents either or both the R and S form of the compound): ##STR00001## where A, B, C, Y.sub.1, Y.sub.2, Z, R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5, W.sub.1, n, p and q are as defined herein. |
| Inventor(s): | Boehm; Marcus F. (San Diego, CA), Martinborough; Esther (San Diego, CA), Moorjani; Manisha (San Diego, CA), Tamiya; Junko (Carlsbad, CA), Huang; Liming (San Diego, CA), Yeager; Adam R. (La Mesa, CA), Brahmachary; Enugurthi (San Diego, CA), Fowler; Thomas (Melton Mowbray, GB), Novak; Andrew (Nottingham, GB), Meghani; Premji (Leicestershire, GB), Knaggs; Michael (Burton-on-Trent, GB) |
| Assignee: | Receptos, Inc. (San Diego, CA) |
| Application Number: | 13/712,624 |
| Patent Claims: | see list of patent claims |
Details for Patent 8,778,923
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Number | Approval Date | Patent No. | Assignee | Estimated Patent Expiration | Status | Orphan | Source |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sanofi-aventis Us | ADLYXIN | lixisenatide | SOLUTION;SUBCUTANEOUS | 208471 | 002 | 2016-07-27 | Start Trial | Receptos, Inc. (San Diego, CA) | 2039-02-26 | RX | search | |
| Sanofi-aventis Us | ADLYXIN | lixisenatide | SOLUTION;SUBCUTANEOUS | 208471 | 001 | 2016-07-27 | Start Trial | Receptos, Inc. (San Diego, CA) | 2039-02-26 | RX | search | |
| Glaxosmithkline Llc | TANZEUM | albiglutide | INJECTABLE;INJECTION | 125431 | 001 | 2014-04-15 | Start Trial | Receptos, Inc. (San Diego, CA) | 2039-02-26 | RX | search | |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Number | >Approval Date | >Patent No. | >Assignee | >Estimated Patent Expiration | >Status | >Orphan | >Source |
International Patent Family for US Patent 8,778,923
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| World Intellectual Property Organization (WIPO) | 2013090454 | Start Trial |
| United States of America | 2013178420 | Start Trial |
| United States of America | 2015038416 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
